Cite
LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC).
MLA
Wang, L., et al. “LBA61 HR070803 plus 5-FU/LV versus Placebo plus 5-FU/LV in Second-Line Therapy for Gemcitabine-Refractory Locally Advanced or Metastatic Pancreatic Cancer: A Multicentered, Randomized, Double-Blind, Parallel-Controlled Phase III Trial (HR-IRI-APC).” Annals of Oncology, vol. 33, Sept. 2022, p. S1426. EBSCOhost, https://doi.org/10.1016/j.annonc.2022.08.063.
APA
Wang, L., Qin, S., Zhou, Y., Zhang, S., Sun, X., Chen, Z., Cui, J., Zhao, P., Gu, K., Li, Z., Wang, J., Chen, X., Yao, J., Shen, L., Zhou, J., Wang, G., Bai, Y., Wang, Q., & Wang, H. (2022). LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC). Annals of Oncology, 33, S1426. https://doi.org/10.1016/j.annonc.2022.08.063
Chicago
Wang, L., S. Qin, Y. Zhou, S. Zhang, X. Sun, Z. Chen, J. Cui, et al. 2022. “LBA61 HR070803 plus 5-FU/LV versus Placebo plus 5-FU/LV in Second-Line Therapy for Gemcitabine-Refractory Locally Advanced or Metastatic Pancreatic Cancer: A Multicentered, Randomized, Double-Blind, Parallel-Controlled Phase III Trial (HR-IRI-APC).” Annals of Oncology 33 (September): S1426. doi:10.1016/j.annonc.2022.08.063.